NCT04356339View on ClinicalTrials.gov

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

August 29, 2021

Study Completion Date

November 11, 2021

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon-beta-1b (BETASERON, BAY 86-5046)

Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician

Trial Locations (1)

07981

myBETAapp, Whippany

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04356339 - US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector | Biotech Hunter | Biotech Hunter